Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in ...

In a landscape where access is no longer an after-thought, but a strategic imperative, this summit tackles the full lifecycle ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and Ultomiris (ravulizumab) – which are dosed by intravenous infusion every two and ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Inizio brings in seasoned pharma exec for top job. A new chapter begins at Inizio with the appointment of Ryan Quigley as CEO ...